# Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

> **NCT00837759** · PHASE2 · TERMINATED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 7 (actual)

## Conditions studied

- Diabetes Mellitus Type 1
- Autoimmune Diabetes

## Interventions

- **DRUG:** Insulin
- **DRUG:** Lansoprazole
- **DRUG:** Sitagliptin
- **BIOLOGICAL:** Diamyd
- **DRUG:** GAD65 (Diamyd)

## Key facts

- **NCT ID:** NCT00837759
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Changes to study personnel.
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837759, "Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00837759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*